Form 4: CURIS CFO Acquires Convertible Stock, Warrants

CURIS CFO Diantha Duvall reported the acquisition of convertible preferred stock and associated warrants, signaling potential future common stock ownership.

Summary

• Diantha Duvall, CFO of CURIS INC (CRIS), acquired 50 shares of Series B Convertible Non-Redeemable Preferred Stock and associated warrants on March 17, 2026.
• Each share of Series B Preferred Stock automatically converts into 1,333.33 shares of Common Stock for no additional consideration at 5 p.m. Eastern Time on March 20, 2026.
• Each Series B Preferred Stock share was sold together with a Series A Warrant, a Series B Warrant, and a Series C Warrant, collectively referred to as a 'Security'.
• The purchase price for each Security was $1,000.00.
• The Series A, B, and C Warrants each grant the right to purchase 1,333.33 shares of Common Stock per preferred share, totaling 66,666 shares for each warrant series.
• The exercise price for all warrants is $0.75 per share, though the Series B Warrant's exercise price is subject to a potential reset.
• All warrants became immediately exercisable on March 17, 2026, following Requisite Stockholder Approval and the Certificate of Amendment Filing.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive signal due to insider buying, indicating management's belief in the company's value, though the warrant terms introduce some complexity.

Positives

• An insider (CFO Diantha Duvall) acquiring a significant stake in the company's equity, including convertible preferred stock and warrants, can be interpreted as a strong vote of confidence in the company's future prospects.
• The transaction represents a capital infusion for the company from an insider.

Negatives

• The Series B Warrant includes a provision for the exercise price to be reset if the closing sale price of the Common Stock at the Initial Termination Date is below $0.75, potentially reducing the exercise price to as low as 50% of the initial price, which could lead to greater dilution if exercised at a lower price.

Risks

• The Series B Warrant's exercise price reset mechanism, which could reduce the exercise price if the common stock price falls below $0.75 at its initial termination date, introduces uncertainty regarding potential future dilution and the value of the warrant.
• The expiration of the Series B Warrants is tied to the progress of the Company's Phase 2 clinical trial of emavusertib, introducing clinical development risk.

Future Outlook

The filing references the Company's Phase 2 clinical trial of emavusertib in combination with an approved Bruton Tyrosine Kinase Inhibitor in chronic lymphocytic leukemia, as the expiration of the Series B Warrants is tied to the dosing of the fifth patient in this trial.

Industry Context

StockSavvy.ai notes that insider purchases, particularly by a Chief Financial Officer, are often interpreted by the market as a positive signal, indicating management's belief in the company's intrinsic value and future prospects. In the biotechnology sector, such confidence can be particularly impactful, especially when tied to the progress of key clinical trials like the emavusertib Phase 2 study mentioned.

Corporate Governance

Related Party Transactions

• The acquisition of Series B Convertible Preferred Stock and associated warrants by Diantha Duvall, the company's CFO, constitutes a related party transaction.

Stakeholder Impact

• Shareholders: The conversion of preferred stock and potential exercise of warrants will lead to an increase in the number of outstanding common shares, potentially causing dilution. However, the insider purchase may also instill confidence.
• Company: Receives capital from the sale of these securities.

Next Steps

• Automatic conversion of Series B Convertible Preferred Stock into Common Stock on March 20, 2026.
• Continued progress of the Company's Phase 2 clinical trial of emavusertib, which will determine the Initial Termination Date for the Series B Warrants.

Key Dates

Recommendation

The acquisition of convertible preferred stock and warrants by the CFO signals insider confidence, which is generally a positive indicator. However, a Form 4 primarily reports a transaction and does not provide a full financial picture or strategic update to warrant a stronger recommendation. The complex terms of the Series B warrant, including a potential exercise price reset, introduce a degree of uncertainty.

Keywords

CURIS INC, CRIS, Form 4, insider transaction, convertible preferred stock, warrants, Diantha Duvall, CFO, equity acquisition, emavusertib